Annual Report

Overview

The report describes FY 2021-22 sales of ₹3,230 crore and Wockhardt's international and research-driven pharmaceutical performance. It highlights six New Chemical Entities under development with QIDP status and the company's collaboration with Serum Life Sciences UK to expand global vaccine manufacturing. The report also emphasizes community programmes and reports a global talent base of approximately 4,000 associates.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021-2022
Period: 1 April 2021 – 31 March 2022
Publication date: 30 May 2022
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Level
Standard
Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services